Oramed Pharmaceuticals
ORMP
35 hedge funds and large institutions have $5.01M invested in Oramed Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 6 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
6% more capital invested
Capital invested by funds: $4.73M → $5.01M (+$280K)
2.72% more ownership
Funds ownership: 5.8% → 8.52% (+2.7%)
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$851K |
| 2 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
+$569K |
| 3 |
Millennium Management
New York
|
+$244K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$206K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$109K |
| 2 |
VF
Virtu Financial
New York
|
-$53.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$14K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$5.49K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$4.17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $9K | -$4.17K | -1,198 | -26% |
|
|
SIAP
27
Sterling Investment Advisors (Pennsylvania)
Berwyn,
Pennsylvania
| $8K | – | – | – |
|
|
28
Wells Fargo
San Francisco,
California
| $7K | -$5.49K | -1,575 | -36% |
|
29
Bank of Montreal
Toronto,
Ontario, Canada
| $4K | – | – | – |
|
|
SFS
30
Sowell Financial Services
North Little Rock,
Arkansas
| $3K | +$575 | +165 | +16% |
|
31
Bank of America
Charlotte,
North Carolina
| $2K | – | – | – |
|
|
JWA
32
JFS Wealth Advisors
Hermitage,
Pennsylvania
| $1K | – | – | – |
|
33
Group One Trading
Chicago,
Illinois
| $1K | +$1.24K | +355 | New |
|
|
34
Millennium Management
New York
| $183 | +$244K | +70,084 | New |
|
|
BFM
35
Boothbay Fund Management
New York
| – | -$109K | -30,963 | Closed |
|
|
TRCT
36
Tower Research Capital (TRC)
New York
| – | -$14K | -4,104 | Closed |
|
|
SPIA
37
Steward Partners Investment Advisory
New York
| – | -$4K | -1,000 | Closed |
|
|
RWB
38
RMR Wealth Builders
Montclair,
New Jersey
| – | -$2K | -450 | Closed |
|
|
TF
39
TimeScale Financial
Danvers,
Massachusetts
| – | +$143 | +41 | +49% |
|
ORMP Hedge Fund Activity: Q3 2020 in Review
35 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2020, worth a combined $5.01M — up 5.9% from $4.73M a quarter earlier.
Fund positioning in ORMP was balanced in Q3 2020: 6 funds opened new positions, 6 closed out, 11 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $851K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $109K sold.
- 35 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $5.01M of Oramed Pharmaceuticals stock for Q3 2020, up 5.9% quarter-over-quarter.
- 6 funds opened new Oramed Pharmaceuticals positions in Q3 2020 and 6 closed out, a net change of 0 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2020 was Renaissance Technologies, an estimated $851K added.
- The largest Oramed Pharmaceuticals seller in Q3 2020 was Boothbay Fund Management, an estimated $109K sold.
Based on aggregated 13F filings for Q3 2020.